June 13 (Reuters) – Johnson & Johnson: * NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)